Lupin has received final approval for its Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Mylan Pharmaceuticals Inc.’s Triamcinolone Acetonide Cream, 0.025% and 0.1%. Lupin shall commence promoting the product shortly. Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% had US sales of $55.7 million, as per IMS MAT Sep 2016.
Lupin’s Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is an AT rated generic equivalent of Mylan Pharmaceuticals, Inc.’s (formerly held by Delcor Asset Corporation) Triamcinolone Acetonide Cream, 0.025% and 0.1%. Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
